Please use this identifier to cite or link to this item:
|Title:||A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women|
|Authors:||Joura, Elmar A;Giuliano, Anna R;Iversen, Ole-Erik;Bouchard, Celine;Mao, Constance;Mehlsen, Jesper;Moreira, Edson D;Ngan, Yuen;Petersen, Lone Kjeld;Lazcano-Ponce, Eduardo;Pitisuttithum, Punnee;Restrepo, Jaime Alberto;Stuart, Gavin;Woelber, Linn;Yang, Yuh Cheng;Cuzick, Jack;Garland, Suzanne M;Huh, Warner;Kjaer, Susanne K;Bautista, Oliver M;Chan, Ivan S F;Chen, Joshua;Gesser, Richard;Moeller, Erin;Ritter, Michael;Vuocolo, Scott;Luxembourg, Alain|
|Abstract:||The investigational 9-valent viruslike particle vaccine against human papillomavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6, 11, 16, and 18) and five additional oncogenic types (31, 33, 45, 52, and 58). Here we present the results of a study of the efficacy and immunogenicity of the 9vHPV vaccine in women 16 to 26 years of age.|
|Appears in Collections:||New England Journal of Medicine 2015|
Items in HannanDL are protected by copyright, with all rights reserved, unless otherwise indicated.